127 related articles for article (PubMed ID: 8402222)
1. Effects of 5-fluorouracil and a combination of tegafur and uracil (UFT) on nucleotide metabolism in L1210 ascites tumor.
Kakito H; Ohkubo T; Kagawa Y; Inagaki S; Sumida K; Ooi K; Higashigawa M; Sakurai M
Cancer Invest; 1993; 11(5):530-3. PubMed ID: 8402222
[TBL] [Abstract][Full Text] [Related]
2. Effects of UFT (mixed compound of tegafur and uracil) on cell kinetics and inhibition of thymidylate synthase in L1210 ascites tumor.
Kagawa Y; Ohkubo T; Higashigawa M; Ido M; Kakito H; Inagaki S; Kojima M; Ooi K; Sakurai M
Cancer Invest; 1995; 13(5):470-4. PubMed ID: 7552812
[TBL] [Abstract][Full Text] [Related]
3. Plasma, intestine and tumor levels of 5-fluorouracil in mice bearing L1210 ascites tumor following oral administration of 5-fluorouracil, UFT (mixed compound of tegafur and uracil), carmofur and 5'-deoxy-5-fluorouridine.
Ooi A; Ohkubo T; Higashigawa M; Kawasaki H; Kakito H; Kagawa Y; Kojima M; Sakurai M
Biol Pharm Bull; 2001 Nov; 24(11):1329-31. PubMed ID: 11725974
[TBL] [Abstract][Full Text] [Related]
4. Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil.
Ho DH; Pazdur R; Covington W; Brown N; Huo YY; Lassere Y; Kuritani J
Clin Cancer Res; 1998 Sep; 4(9):2085-8. PubMed ID: 9748123
[TBL] [Abstract][Full Text] [Related]
5. [Studies on the mechanism of antitumor activity of 5-FU and its derivatives--relationship between the inhibition of tumor growth and the inhibition of thymidylate synthetase in vivo].
Nakamura H; Yu-Qin W; Miyauchi S; Nishioka N; Tanaka H; Harada N; Shirasaka T; Fujii S
Gan To Kagaku Ryoho; 1984 May; 11(5):1049-55. PubMed ID: 6426401
[TBL] [Abstract][Full Text] [Related]
6. Effect of methotrexate and 1-beta-D-arabinofuranosylcytosine on pools of deoxyribonucleoside triphosphates in L1210 ascites cells.
Roberts D; Peck C
Cancer Res; 1981 Feb; 41(2):505-10. PubMed ID: 7448798
[TBL] [Abstract][Full Text] [Related]
7. Studies on the metabolism of 1-(2-tetrahydrofuryl)-5-fluorouracil and uracil co-administered orally to tumor-bearing rats.
Kawaguchi Y; Nagayama S; Masuda H; Yasuda A
Gan; 1980 Dec; 71(6):889-99. PubMed ID: 6791982
[TBL] [Abstract][Full Text] [Related]
8. UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer.
Hoff PM; Pazdur R; Benner SE; Canetta R
Anticancer Drugs; 1998 Jul; 9(6):479-90. PubMed ID: 9877235
[TBL] [Abstract][Full Text] [Related]
9. [Relationship between the anti-metastatic effect of UFT and in vitro chemosensitivity to 5-FU in metastatic tumors from orthotopic implanted colon cancer in nude rats].
Ogata Y; Akagi Y; Nozoe Y; Sasatomi T; Miyagi Y; Nakagawa M; Matono K; Kobayashi H; Shirouzu K
Gan To Kagaku Ryoho; 2001 May; 28(5):655-60. PubMed ID: 11383214
[TBL] [Abstract][Full Text] [Related]
10. Dipyridamole augments the antitumor effects of fluorinated pyrimidines.
Sakaguchi Y; Kusumoto T; Kusumoto H; Maehara Y; Furusawa M; Sugimachi K
Anticancer Res; 1992; 12(1):119-21. PubMed ID: 1567156
[TBL] [Abstract][Full Text] [Related]
11. [Level of inhibition of thymidylate synthase activity and 5-fluorouracil in tumor tissues after administration of UFT or tegafur].
Suzuki M; Sekiguchi I; Tamada T; Nishida M
Nihon Gan Chiryo Gakkai Shi; 1989 Jul; 24(7):1399-404. PubMed ID: 2530293
[TBL] [Abstract][Full Text] [Related]
12. [Level of 5-FU in cancerous and normal tissues of nude mice after oral administration of tegafur coadministered with uracil (UFT)].
Sekiguchi I; Suzuki M; Tamada T; Nishida M
Gan To Kagaku Ryoho; 1985 May; 12(5):1094-8. PubMed ID: 3922312
[TBL] [Abstract][Full Text] [Related]
13. [Drug concentration in cancerous large bowel tissue and thymidylate synthase inhibition rate after administration of tegafur and UFT].
Futami K; Arima S; Yoshimura S; Okamoto T; Yamasaki K; Koto T; Yamasaki S; Kawahara K; Ikuno T
Gan To Kagaku Ryoho; 1991 Feb; 18(2):215-20. PubMed ID: 1992915
[TBL] [Abstract][Full Text] [Related]
14. [Pharmacokinetics and a phase I study of tegafur-uracil enterogranules in cancer patients].
Kamiya O; Hoshino A; Ohara K; Nagata K; Kojima T; Sugihara T; Yamada M; Suzuki M; Kimura K; Fujii S
Gan To Kagaku Ryoho; 1983 Dec; 10(12):2565-72. PubMed ID: 6418079
[TBL] [Abstract][Full Text] [Related]
15. Sensitivity test for 5-fluorouracil and its analogues, 1-(2-tetrahydrofuryl)-5-fluorouracil, uracil/1-(2-tetrahydrofuryl)-5-fluorouracil (4:1) and 1-hexylcarbamoyl-5-fluorouracil, using the subrenal capsule assay.
Anai H; Maehara Y; Kusumoto H; Kusumoto T; Sugimachi K
Oncology; 1988; 45(3):144-7. PubMed ID: 3130595
[TBL] [Abstract][Full Text] [Related]
16. General pharmacological properties of UFT, a new type of anti-cancer agent consisting of 1-(2-tetrahydrofuryl)-5-fluorouracil (FT) and uracil. I: Pharmacological analysis of the combined effect of FT and uracil.
Yamamoto J; Toide K; Haruno A; Yoshimura Y; Unemi N
Arzneimittelforschung; 1981; 31(8):1268-78. PubMed ID: 6794578
[TBL] [Abstract][Full Text] [Related]
17. UFT is more antineoplastic against gastric carcinoma than 5-fluorouracil, 1-(2-tetrahydrofuryl)-5-fluorouracil and 1-hexylcarbamoyl-5-fluorouracil.
Maehara Y; Kusumoto T; Kusumoto H; Anai H; Sugimachi K
Chemotherapy; 1988; 34(6):484-9. PubMed ID: 3149571
[TBL] [Abstract][Full Text] [Related]
18. 5-Ethynyluracil (776C85): effects on the antitumor activity and pharmacokinetics of tegafur, a prodrug of 5-fluorouracil.
Cao S; Baccanari DP; Joyner SS; Davis ST; Rustum YM; Spector T
Cancer Res; 1995 Dec; 55(24):6227-30. PubMed ID: 8521418
[TBL] [Abstract][Full Text] [Related]
19. [5-Fluorouracil, tegafur, and uracil concentrations in serum and tissue of the patients with hepatocellular carcinoma after UFT administration].
Suenaga M
Gan To Kagaku Ryoho; 1987 Dec; 14(12):3313-8. PubMed ID: 2825604
[TBL] [Abstract][Full Text] [Related]
20. A Pharmacokinetic-Pharmacodynamic Model Predicts Uracil-tegafur Effect on Tumor Shrinkage and Myelosuppression in a Colorectal Cancer Rat Model.
Kobuchi S; Tsuda M; Okamura M; Nakamura T; Ito Y
Anticancer Res; 2023 Mar; 43(3):1121-1130. PubMed ID: 36854515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
